Home » General » Boston Scientific Boosts Patent Portfolio with BTG Acquisition

Boston Scientific Boosts Patent Portfolio with BTG Acquisition

British Technology Group (now BTG plc), known for producing drugs to treat overdoses and rattlesnake bites, was formed in 1981 as a result of the merger of the National Research & Development Council and the National Enterprise Board of the UK government. A range of medical innovations along the way and several acquisitions later, BTG today is an international healthcare company focused on interventional medicine.

In late November 2018, Boston Scientific Corporation (BSC) announced that it would be acquiring BTG plc for USD 4.2 billion. Boston Scientific manufactures medical devices with interventional medical specialities. The acquisition will help Boston Scientific enhance its technology coverage and capabilities in interventional medicine.

In this report, we take a closer look at the patent portfolios of BTG and BSC using the taxonomy analytics generated by Relecura.

An Overview

Figure 1: BTG – Published Applications – Growth [Click on the image to enlarge]

BTG owns a patent portfolio of 1,487 active applications, which is about 9% the number of the total patent assets held by BSC (16,849 active applications). Figure 1 gives the publication trend of BTG’s patent portfolio.

Figure 2: BTG – Interventional Devices – Growth [Click on the image to enlarge]

BTG has a relatively small patent portfolio. However, the patent assets related to interventional medicine and devices in its portfolio are of high quality. Figure 2 depicts the growth of its published patent assets covering interventional devices. 

The report includes a detailed comparison of the portfolios of BTG and BSC. The comparison determines the value that acquiring BTG’s portfolio brings to BSC’s current patent assets. It shows how well the patent portfolios of both the companies complement each other and takes a closer look at the patent quality of the assets held by each.

The report considers the different M&A IP scenarios that might have played out. These include attempting to determine which other companies could have been potential acquirers for BTG. On the flip side, it analyzes other options that Boston Scientific might have considered as potential acquisitions, that were comparable to BTG from an IP standpoint.

Read our report to get all the analysis details and insights.

Get the complete report here.

The contents of this report were referenced in an IAM article. To read the article, click here

Leave a Reply

Your email address will not be published. Required fields are marked *

Name *
Email *